EUVIMEDEUVIMED entdecken
Crossref

Physician Perception of Grade Group 1 Prostate Cancer

Ragheed Saoud, Varat Woranisarakul, Gladell P Paner, Matthew Ramotar, Alejandro Berlin, Matthew Cooperberg, Scott E Eggener

European Urology Focus · 2023-11 · 9 (6) · 966-973

DOI: 10.1016/j.euf.2023.04.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2023-11. Verfasst von Ragheed Saoud und 6 weiteren Autor:innen. Beteiligte Einrichtung: Arthur Smith Institute of Urology, Northwell Health, Riverhead, NY, USA. Electronic address: rsaoud@northwell.edu. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Urology. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite its low-risk nature, grade group 1 (GG 1) prostate cancer (PCa) remains overtreated. This suggests a disconnect between daily physician practice and the standard of care. We hypothesized that GG 1 disease is overtreated because of common misconceptions regarding its true natural history. OBJECTIVE: To survey physicians worldwide to better understand their approach to management of GG 1 PCa. DESIGN, SETTING, AND PARTICIPANTS: A 17-question survey was sent to urology, radiation oncology, and pathology societies on six continents, and was posted on Twitter. Responses were collected and analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pearson's χ2 test was used to assess correlation between physician-related variables and the perception of active surveillance (AS) for GG 1 PCa. Logistic regression was used for multivariable analysis. Statistical analysis was performed using SPSS version 21. RESULTS AND LIMITATIONS: Among 1303 participants, 55% were urologists, 47% had completed fellowship, and 49% practice in an academic setting. Among the clinicians, 724 (83%) routinely recommend AS for GG 1 PCa and have never/rarely regretted it, while 18 (2%) "often" regretted it. Routine AS was more common among physicians aged 3%. Regarding reclassification of GG 1 to a precancerous lesion, 428 (39%) felt that this is a good idea, 340 (31%) disagreed, and 323 (30%) were uncertain. Those in support were more likely to be aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsUrologyMaleHumansNeoplasm GradingUrologistsPerception

Stichwörter der Autor:innen

Gleason 6 surveillanceGleason gradeProstate cancer

Autor:innen und Institutionen

  • Arthur Smith Institute of Urology, Northwell Health, Riverhead, NY, USA. Electronic address: rsaoud@northwell.edu.
  • Department of Surgery, Division of Urology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Pathology, University of Chicago Medicine, Chicago, IL, USA.
  • Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada.
  • Departments of Urology and Epidemiology & Biostatistics, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA.
  • Section of Urology, University of Chicago Medicine, Chicago, IL, USA.

Zitieren

APA

Saoud, R., Woranisarakul, V., Paner, G. P., Ramotar, M., Berlin, A., Cooperberg, M., & Eggener, S. E. (2023). Physician Perception of Grade Group 1 Prostate Cancer. European Urology Focus, 9(6), 966-973. https://doi.org/10.1016/j.euf.2023.04.002

Vancouver

Saoud R, Woranisarakul V, Paner GP, Ramotar M, Berlin A, Cooperberg M, et al. Physician Perception of Grade Group 1 Prostate Cancer. European Urology Focus. 2023;9(6):966-973. doi:10.1016/j.euf.2023.04.002

BibTeX
@article{Saoud2023,
  author = {Saoud, Ragheed and Woranisarakul, Varat and Paner, Gladell P and Ramotar, Matthew and Berlin, Alejandro and Cooperberg, Matthew and Eggener, Scott E},
  title = {Physician Perception of Grade Group 1 Prostate Cancer},
  journal = {European Urology Focus},
  year = {2023},
  volume = {9},
  number = {6},
  pages = {966--973},
  doi = {10.1016/j.euf.2023.04.002}
}
Kostenlos starten →